Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Highly Accessed Editorial

Green tea: a new option for the prevention or control of osteoarthritis

Santosh K Katiyar12* and Chander Raman3

Author Affiliations

1 Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA

2 Birmingham VA Medical Center, Birmingham, AL 35294, USA

3 Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA

For all author emails, please log on.

Arthritis Research & Therapy 2011, 13:121  doi:10.1186/ar3428

Published: 10 August 2011

Abstract

IL-1β is a major cytokine driving the inflammatory processes leading to the pathophysiology of osteoarthritis and other inflammatory diseases. Blockade of IL-1β activity using substances such as the naturally occurring IL-1 receptor antagonist or anti-IL-1β monoclonal antibody are currently being used or tested as therapy. However, such treatments are ineffective in osteoarthritis. In a recent study, epigallocatechin-3-gallate, a green tea polyphenol, was found to be effective in reducing IL-1β-induced inflammatory cytokines, TNFα, IL-6, granulocyte-macrophage colony-stimulating factor and several chemokines from human chondrocytes. The use of green tea polyphenols may be beneficial as a therapeutic addition to biologics that control IL-1β activity by increasing effectiveness and/or reducing dosage.